Metrics as of 10/13/2026, 06:32 PM (Berlin time), refresh in progress.
Lunai Bioworks Stock
Lunai Bioworks Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David H. Weinstein
- Employees
- 29
- Market cap
- $5 M
- IPO
- 30/09/2025
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity…
Lunai Bioworks stock: price history
1D
-6.3%
1W
-8.0%
1M
-56.3%
6M
-61.6%
YTD
-85.2%
1Y
-88.8%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~12% weaker price swings than usual
Ask the agents about Lunai Bioworks
Lunai Bioworks stock metrics
P/E
-0.02
P/B
-0.34
EV/EBITDA
-0.02
RETURN ON EQUITY
26.9%
NET MARGIN
-12,278.6%
DEBT/EQUITY
-0.15
DIVIDEND YIELD
0.0%
AS OF
31/03/2026
Free float & liquidity
FREE FLOAT
55.6%
FLOAT SHARES
2,520,770
AVG. DAILY VOLUME (30D)
74,573
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Lunai Bioworks stock
What does Lunai Bioworks do?
Lunai Bioworks Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David H. Weinstein, the company employs around 29 people.
The IPO was on 30/09/2025; the stock trades on NASDAQ under the ticker LNAI.
When does Lunai Bioworks report next?
Around past earnings, price swings were roughly -12% stronger than usual.
Does Lunai Bioworks pay a dividend?
No, Lunai Bioworks currently does not pay a dividend.
Which stocks are comparable to Lunai Bioworks?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Lunai Bioworks stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lunai Bioworks against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.